Related Experiment Videos
Alteplase therapy in acute ischemic stroke: a Danish pilot study.OFF
G Boysen1, K Overgaard, B Sperling
1Department of Neurology, University Hospital, Rigshospitalet, Odense, Denmark.
Zeitschrift Fur Kardiologie
|January 1, 1993
Summary
Recombinant tissue plasminogen activator (rt-PA) shows promise for acute ischemic stroke treatment. Early intervention with rt-PA in stroke patients correlated with greater clinical improvement and successful reperfusion.
Area of Science:
- Neurology
- Cardiovascular Medicine
- Radiology
Background:
- Acute ischemic stroke is a time-sensitive medical emergency.
- Recombinant tissue plasminogen activator (rt-PA) is a thrombolytic agent used in stroke treatment.
- Early reperfusion is critical for improving outcomes in ischemic stroke.
Purpose of the Study:
- To evaluate the efficacy and safety of intravenous rt-PA in acute ischemic stroke patients.
- To assess the correlation between treatment delay and clinical outcomes.
- To measure regional cerebral blood flow changes after rt-PA therapy.
Main Methods:
- An open pilot study involving 23 acute ischemic stroke patients treated with rt-PA.
- Treatment administered intravenously within a median of 205 minutes from symptom onset.
- Regional cerebral blood flow measured using 99mTc-HMPAO in 12 patients before and after therapy.
Main Results:
- Reperfusion of the ischemic area was achieved in 10 out of 12 assessed patients.
- Clinical improvement was significantly greater in patients treated earlier after symptom onset.
- Three patients (13%) died due to causes including parenchymatous hematoma and myocardial infarction.
Conclusions:
- Intravenous rt-PA can facilitate reperfusion in acute ischemic stroke.
- Timely administration of rt-PA is associated with better clinical outcomes.
- Further research is warranted to optimize rt-PA treatment protocols for stroke.